Competition intensifies in already crowded multiple sclerosis space
05/09/19 -"Novartis’ Arzerra is all set to enter the fast-growing/crowded MS space (likely in 2020) banking on superior clinical data vs. Sanofi’s Aubagio. While this would dent the sales of Aubagio, Novartis’ ..."
Pages
69
Language
English
Published on
05/09/19
You may also be interested by these reports :
22/10/26
The Q3 sales were ahead of the street’s expectations, driven by healthy growth across both segments. The beat, though, received support from a ...
22/10/26
Ipsen reported a robust Q3, resulting in an upgraded 2026 guidance. While we may revise our estimates upwards, we do not anticipate a significant ...
22/10/26
A guidance upgrade on top of the modest outlook uplift in July 2026 reflects UCB’s habit of making modest promises and then over-delivering. ...
20/10/26
The Q3 sales growth surpassed the full-year guidance range, backed by healthy growth in companion and farm animal segments across geographies. The ...